New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 2, 2014
08:49 EDTACT, FURXActavis completes acquisition of Furiex
Actavis (ACT) announced that its subsidiary Forest Laboratories has successfully completed its acquisition of Furiex Pharmaceuticals (FURX) in an all-cash transaction valued at approximately $1.1B, and up to approximately $360M in a Contingent Value Right that may be payable based on the status of eluxadoline, Furiex's product, as a controlled drug following approval. In connection with the close of the Furiex acquisition, Actavis further announced that it has closed the transaction related to the sale of Furiex's royalties on alogliptin and Priligy to Royalty Pharma for approximately $415M.
News For ACT;FURX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for ACT;FURX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use